Yaohua Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yaohua Chen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Fang Wu
Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, China
1 shared publication - Fudao Wu
Department of Oncology, Dazhou Central Hospital, Dazhou, China
1 shared publication - Guirong Wu
Department of Oncology, Dazhou Central Hospital, Dazhou, China
1 shared publication - Jiang Wang
Department of Oncology, Dazhou Central Hospital, Dazhou, China
1 shared publication - Jiangping Fu
Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Southwest Medical University, China
1 shared publication - Jie Li
Department of Clinical Research Center, Dazhou Central Hospital, Dazhou, China
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 24
Prediction of the Efficacy and Prognosis of Anlotinib in Lung Cancer Patients Using CT Radiomics
Purpose: Our study aimed to develop and validate a predictive model based on chest CT radiomics features combined with clinical variables to evaluate the efficacy of anlotinib and its prognostic value in patients with advanced lung cancer. Methods: This single-center retrospective study included 68 patients with advanced lung cancer who received anlotinib monotherapy at a tertiary grade-A hospital in China between January 2021 and July 2024. All patients had experienced disease progression after receiving standardized chemotherapy, targeted therapy, or immunotherapy prior to enrollment, had not undergone radiotherapy, and had completed all prior treatments at our hospital. Chest CT scans were performed before anlotinib treatment, and radiomics features were extracted. Based on treatment response, patients were grouped, and a radiomics model, a clinical model, and a combined model were constructed. Model performance was evaluated using receiver operating characteristic (ROC) curves, the Hosmer–Lemeshow test, calibration curves, and decision curve analysis (DCA), with internal validation performed via bootstrap resampling (500 iterations). Additionally, Kaplan–Meier survival curves were generated for the high- and low-risk groups predicted by the combined model, and survival differences were compared using the log-rank test. Results: The areas under the ROC curve (AUCs) for the radiomics, clinical, and combined models were 0.721, 0.812, and 0.866, respectively, with the combined model significantly outperforming the other two models (DeLong test, P < .05). Internal validation showed an AUC of 0.866 (95% CI: 0.751-0.967) for the combined model. The integrated model demonstrated good calibration via Hosmer-Lemeshow testing ( χ² = 7.81, P = .553) and showed significant clinical net benefit within the threshold probability range of 0.15-0.85 on decision curve analysis. Survival analysis revealed statistically significant differences between the actual treatment-responsive and non-responsive groups (log-rank P < .05), as well as between the model-predicted high-risk and low-risk groups (log-rank P < .05). Multivariable Cox regression confirmed the nomogram score derived from the integrated model as an independent predictor of overall survival (HR = 1.263, 95% CI: 1.090-1.463, P = .002). Conclusion: The combined model incorporating chest CT radiomics features and clinical characteristics demonstrated high accuracy and clinical utility in predicting the efficacy and prognosis of anlotinib treatment in patients with advanced lung cancer.
- 1 June 2025
- Published by SAGE Publications in Technology in Cancer Research & Treatment
- Vol. 24
Open AccessPrediction of the Efficacy and Prognosis of Anlotinib in Lung Cancer Patients Using CT Radiomics
Purpose: Our study aimed to develop and validate a predictive model based on chest CT radiomics features combined with clinical variables to evaluate the efficacy of anlotinib and its prognostic value in patients with advanced lung cancer. Methods: This single-center retrospective study included 68 patients with advanced lung cancer who received anlotinib monotherapy at a tertiary grade-A hospital in China between January 2021 and July 2024. All patients had experienced disease progression after receiving standardized chemotherapy, targeted therapy, or immunotherapy prior to enrollment, had not undergone radiotherapy, and had completed all prior treatments at our hospital. Chest CT scans were performed before anlotinib treatment, and radiomics features were extracted. Based on treatment response, patients were grouped, and a radiomics model, a clinical model, and a combined model were constructed. Model performance was evaluated using receiver operating characteristic (ROC) curves, the Hosmer–Lemeshow test, calibration curves, and decision curve analysis (DCA), with internal validation performed via bootstrap resampling (500 iterations). Additionally, Kaplan–Meier survival curves were generated for the high- and low-risk groups predicted by the combined model, and survival differences were compared using the log-rank test. Results: The areas under the ROC curve (AUCs) for the radiomics, clinical, and combined models were 0.721, 0.812, and 0.866, respectively, with the combined model significantly outperforming the other two models (DeLong test, P < .05). Internal validation showed an AUC of 0.866 (95% CI: 0.751-0.967) for the combined model. The integrated model demonstrated good calibration via Hosmer-Lemeshow testing ( χ² = 7.81, P = .553) and showed significant clinical net benefit within the threshold probability range of 0.15-0.85 on decision curve analysis. Survival analysis revealed statistically significant differences between the actual treatment-responsive and non-responsive groups (log-rank P < .05), as well as between the model-predicted high-risk and low-risk groups (log-rank P < .05). Multivariable Cox regression confirmed the nomogram score derived from the integrated model as an independent predictor of overall survival (HR = 1.263, 95% CI: 1.090-1.463, P = .002). Conclusion: The combined model incorporating chest CT radiomics features and clinical characteristics demonstrated high accuracy and clinical utility in predicting the efficacy and prognosis of anlotinib treatment in patients with advanced lung cancer.
- Open Access
- 30 August 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-20
Construction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer
Background Non-small cell lung cancer (NSCLC) is the most common type of tumor globally and the leading cause of cancer-related deaths. Although treatment strategies such as immune checkpoint inhibitors and chemotherapy have advanced, the heterogeneity among NSCLC patients results in significant variability in treatment outcomes. Studies have shown that certain patients respond poorly to immune checkpoint inhibitors, indicating that treatment response is closely related to multiple factors. Therefore, it is necessary to develop predictive models to stratify patients based on gene expression and clinical characteristics, aiming for precision therapy. Objective This study aims to construct a stratified prognostic model for NSCLC patients based on lysosome-dependent cell death (LDCD) scoring by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data. By analyzing the immune-related characteristics of high-risk and low-risk groups, we further explored the impact of cell death patterns on lung cancer and identified potential therapeutic targets. Methods This study obtained single-cell RNA sequencing data and gene expression data of NSCLC patients and normal lung tissues from the GEO and TCGA databases. We used R packages such as Seurat and CellChat for data preprocessing and analysis, and performed dimensionality reduction and visualization through Principal Component Analysis (PCA) and UMAP algorithms. LASSO regression analysis was used to construct the predictive model, followed by cross-validation and ROC curve analysis. The model’s effectiveness was validated through survival analysis and immune microenvironment analysis. Results The study showed a significant increase in the proportion of monocytes in NSCLC tissues, suggesting their important role in cancer progression. Cell communication analysis indicated that macrophages, smooth muscle cells, and myeloid cells exhibit strong intercellular communication during cancer progression. Using the constructed prognostic model based on 12 LDCD-related genes, we found significant differences in overall survival and immune microenvironment between the high-risk and low-risk groups.
- 30 August 2024
- Published by Springer Nature in Discover Oncology
- Vol. 15 (1) , 1-20
Open AccessConstruction and analysis of a lysosome-dependent cell death score-based prediction model for non-small cell lung cancer
Background Non-small cell lung cancer (NSCLC) is the most common type of tumor globally and the leading cause of cancer-related deaths. Although treatment strategies such as immune checkpoint inhibitors and chemotherapy have advanced, the heterogeneity among NSCLC patients results in significant variability in treatment outcomes. Studies have shown that certain patients respond poorly to immune checkpoint inhibitors, indicating that treatment response is closely related to multiple factors. Therefore, it is necessary to develop predictive models to stratify patients based on gene expression and clinical characteristics, aiming for precision therapy. Objective This study aims to construct a stratified prognostic model for NSCLC patients based on lysosome-dependent cell death (LDCD) scoring by integrating single-cell RNA sequencing (scRNA-seq) and bulk RNA sequencing data. By analyzing the immune-related characteristics of high-risk and low-risk groups, we further explored the impact of cell death patterns on lung cancer and identified potential therapeutic targets. Methods This study obtained single-cell RNA sequencing data and gene expression data of NSCLC patients and normal lung tissues from the GEO and TCGA databases. We used R packages such as Seurat and CellChat for data preprocessing and analysis, and performed dimensionality reduction and visualization through Principal Component Analysis (PCA) and UMAP algorithms. LASSO regression analysis was used to construct the predictive model, followed by cross-validation and ROC curve analysis. The model’s effectiveness was validated through survival analysis and immune microenvironment analysis. Results The study showed a significant increase in the proportion of monocytes in NSCLC tissues, suggesting their important role in cancer progression. Cell communication analysis indicated that macrophages, smooth muscle cells, and myeloid cells exhibit strong intercellular communication during cancer progression. Using the constructed prognostic model based on 12 LDCD-related genes, we found significant differences in overall survival and immune microenvironment between the high-risk and low-risk groups.